No Easy Fix for Pfizer
A mixture of disappointing deals, poor marketing and bad luck, unfolding during a plague of patent expirations, has put long-term investors in Pfizer (PFE) in a bind and analysts in a surly mood.
Over the past five years, Pfizer's stock is down 28%, lagging both the S&P 500-stock index and the Amex Pharmaceutical Index, which contains Big Pharma stocks, including Pfizer.
Even under Jeffrey Kindler, who has been restructuring the company since becoming CEO in July 2006, shares are off 15% in the last 12 months.
While analysts have been grumbling, however, drug-industry management experts are more optimistic -- or at least less anxious -- about Pfizer's turnaround prospects, given its financial strength and still-strong credit rating."It's fixable. They have tons of cash sitting in the bank," says Prof. Mahmud Hassan, director of the pharmaceutical MBA program at Rutgers, the state university of New Jersey, who tells investors to be patient. "Most investors are myopic," he says. "Look at the Vioxx situation. When people saw Vioxx wasn't as big a problem as they thought, Merck's (MRK) stock picked up." Merck and Schering-Plough (SGP), which is cleaning up past regulatory problems, have had more dramatic setbacks than Pfizer, but they have since become more attractive to Wall Street.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV